

Specialty	NICE / AWMSG Reference	Medicine, Generic Name	Indication	Age Range	Blueteq Form
Pulmonology/ Cardiology	AWMSG 4819	Ambrisentan	Treatment of pulmonary arterial hypertension (PAH)	(8-99)	In development
Dermatology	HST28	Birch bark extract	For treatment of skin wounds associated with dystrophic and junctional epidermolysis bullosa	(6 months-99)	In development
Neurology	CP254 WHSSC Policy	Bevacizumab	Treatment of vestibular schwannoma in neurofibromatosis type 2	(0-99)	In development
Neurology	AWMSG 4614	Brivaracetam	Treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy	(2-17)	In development
Renal	TA809	Imlifidase	For desensitisation treatment before kidney transplant in people with chronic kidney disease	(18-99)	In development
Renal	AWMSG 4804	Mercaptamine Bitartrate	Treatment of proven nephropathic cystinosis. Mercaptamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	(0-17)	In development
Metabolic Disorder	AWMSG 2322	Nitisinone	Treatment of adult patients with alkaptonuria	(16-99)	In development
Haematology	PP237 WHSSC Policy	Rituximab / Eculizumab	Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in people with haemoglobinopathies	(0-99)	In development
Pulmonology/ Cardiology	AWMSG 700	Selexipag	Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies	(18-99)	In development